EP Patent

EP1430027B1 — Novel aminoazetidine, -pyrrolidine and -piperidine derivatives

Assigned to vTv Therapeutics LLC · Expires 2010-09-01 · 16y expired

What this patent protects

Novel aminoazetidine, -pyrrolidine, and -piperidine derivatives of the general formula (I): use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compo…

USPTO Abstract

Novel aminoazetidine, -pyrrolidine, and -piperidine derivatives of the general formula (I): use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.

Drugs covered by this patent

Patent Metadata

Patent number
EP1430027B1
Jurisdiction
EP
Classification
—
Expires
2010-09-01
Drug substance claim
No
Drug product claim
No
Assignee
vTv Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.